`
`
`
`
`
`
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`
`
`BEFORE THE PATENT TRIAL AND APPEAL
`BOARD
`
`HOPEWELL PHARMA VENTURES, INC.,
`Petitioner,
`
`v.
`
`MERCK SERONO SA,
`Patent Owner.
`
`Case IPR2023-00481
`U.S. Patent 8,377,903
`
`PATENT OWNER’S UNOPPOSED MOTION TO SEAL
`
`1
`
`
`
`I.
`
`INTRODUCTION
`
`
`
`IPR2023-00481
`Motion to Seal
`
`
`Under 37 C.F.R. §§ 42.54 and 42.14, Patent Owner, Merck Serono SA,
`
`hereby moves to seal Patent Owner’s Demonstrative Exhibits, Paper 56,
`
`submitted on June 20, 2024. Good cause to seal Patent Owner’s
`
`Demonstratives exists because they include excerpts of documents containing
`
`highly confidential, competitively sensitive information of Patent Owner,
`
`which Patent Owner designated as “PROTECTIVE ORDER MATERIAL.”
`
`Patent Owner previously moved for entry of the Board’s Default Protective
`
`Order with Petitioner’s consent. Paper 19. Patent Owner and Petitioner
`
`previously moved to seal documents that are excerpted in Patent Owner’s
`
`Demonstrative Exhibits. Papers 19, 42.
`
`II. AUTHORIZATION FOR THIS MOTION
`
`Prior Board authorization is not required for “motions where it is
`
`impractical for a party to seek prior Board authorization.” Consolidated Trial
`
`Practice Guide (Nov. 20, 2019) (the “Consolidated Trial Practice Guide”), p.
`
`37. “Motions where it is not practical to seek prior Board authorization
`
`include motions to seal. . . .” Id.
`
`III. CERTIFICATION OF CONFERENCE
`
`Under 37 C.F.R. § 42.54, Patent Owner, through the undersigned,
`
`
`
`- 2 -
`
`
`
`hereby certifies that it has conferred with Petitioner through counsel on June
`
`IPR2023-00481
`Motion to Seal
`
`
`20, 2024 in good faith regarding this motion. Petitioner does not oppose
`
`Patent Owner’s Motion to Seal.
`
`IV. GOOD CAUSE EXISTS FOR SEALING PATENT OWNER’S
`DEMONSTRATIVE EXHIBITS
`The Board may issue protective orders for good cause to protect a
`
`party from disclosing confidential information. Consolidated Trial Practice
`
`Guide, pp. 19-20; 37 C.F.R. § 42.54. In deciding whether to grant a motion
`
`to seal, the Board must find “good cause,” and must “strike a balance
`
`between the public’s interest in maintaining a complete and understandable
`
`file history and the parties’ interest in protecting truly sensitive information.”
`
`Garmin International, Inc. et al. v. Cuozzo Speed Technologies LLC,
`
`IPR2012-00001, Paper 36 at 4 (P.T.A.B. April 5, 2013). “Confidential
`
`Information” is identified in a manner consistent with Fed. R. Civ. P.
`
`26(c)(1)(G), “which provides for protective orders for trade secret or other
`
`confidential research, development, or commercial information.” Id.
`
`Good cause for sealing material can be established by demonstrating
`
`that the balance of the following considerations favors sealing the material:
`
`whether (1) the information sought to be sealed is truly confidential, (2) a
`
`concrete harm would result upon public disclosure, (3) there exists a genuine
`
`
`
`- 3 -
`
`
`
`need to rely in the trial on the specific information sought to be sealed, and
`
`IPR2023-00481
`Motion to Seal
`
`
`(4), on balance, an interest in maintaining confidentiality outweighs the
`
`strong public interest in having an open record. See Argentum Pharms. LLC
`
`v. Alcon Research, Ltd., IPR2017-01053, Paper 27 at 4 (P.T.A.B. January 19,
`
`2018).
`
`Patent Owner’s Demonstrative Exhibits, Paper 56, contain confidential
`
`research, development, or business information designated as “PROTECTIVE
`
`ORDER MATERIAL” under the Default Protective Order that was agreed-
`
`upon by the parties. Specifically, it contains confidential excerpts of Exhibits
`
`1063, 2049, and 2050, which Patent Owner and Petitioner previously moved
`
`to seal. Papers 19, 42. The balance of the Argentum factors favors sealing
`
`Patent Owner’s Demonstrative Exhibits.
`
`a. Patent Owner’s Demonstrative Exhibits Contain
`Confidential Information
`The information Patent Owner seeks to seal in Patent Owner’s
`
`Demonstrative Exhibits is “truly confidential.” See Fed. R. Civ. P.
`
`26(c)(1)(G). Patent Owner’s Demonstrative Exhibits contain confidential
`
`technical information regarding drug development of Patent Owner and non-
`
`parties to this proceeding. The information contained in Patent Owner’s
`
`Demonstrative Exhibits is subject to non-party confidentiality obligations
`
`
`
`- 4 -
`
`
`
`(e.g., with development partners and Patent Owner’s affiliate) or would cause
`
`IPR2023-00481
`Motion to Seal
`
`
`competitive business harm to Patent Owner if publicly disclosed.
`
`First, Patent Owner’s Demonstrative Exhibits include excerpts of the
`
`December 17, 2003, Briefing Document (Ex. 2049), which is a true and
`
`correct copy of an email communication and attachment sent from Serono to
`
`IVAX and Serono personnel on December 17, 2003 and concerns the subject
`
`matter of the IVAX-Serono Agreement, Ex. 2048. The communication
`
`contains a highly confidential draft “Briefing Document” concerning
`
`Serono’s development plan for an oral cladribine drug product, including
`
`Patent Owner’s confidential technical data, research data, and prospective
`
`research and clinical development plans. See Ex. 2049.
`
`Second, Patent Owner’s Demonstrative Exhibits include excerpts of
`
`the August 27, 2003, Meeting Minutes (Ex. 2050), which is a true and correct
`
`copy of confidential meeting minutes between IVAX’s and Serono’s drug
`
`development teams held on August 27, 2003, concerning the subject matter
`
`of the IVAX-Serono Agreement, Ex. 2048. The August 27, 2003, Meeting
`
`Minutes includes highly confidential information related to the ongoing
`
`development of the joint research efforts of Ares Trading S.A. and IVAX,
`
`including technical data reports and prospective research and clinical
`
`development plans. See Ex. 2050.
`
`
`
`- 5 -
`
`
`
`Third, Patent Owner’s Demonstrative Exhibits include excerpts of the
`
`IPR2023-00481
`Motion to Seal
`
`
`Deposition Transcript of Dr. Munafo (Exhibit 1063), which includes
`
`quotations, paraphrasing, and characterization of confidential portions of
`
`Exhibits 2048, 2049, and 2050, all of which Patent Owner previously moved
`
`to seal, as well as testimony concerning the joint research and development
`
`obligations for investigational cladribine oral formulations, dosing regimens,
`
`and clinical studies and Serono’s development plan for an oral cladribine
`
`drug product, including Patent Owner’s confidential technical data, research
`
`data, and prospective research and clinical development plans, none of which
`
`been made publicly available. See Ex. 1063.
`
`The excerpts of Exhibits 1063, 2049, and 2050 included in Patent
`
`Owner’s Demonstrative Exhibits include confidential information relating to
`
`Serono’s development plan for an oral cladribine drug product, including
`
`Patent Owner’s confidential prospective research and clinical development
`
`plans, which have not been made publicly available. See Paper 56.
`
`Therefore, the contents of Patent Owner’s Demonstrative Exhibits
`
`constitute “trade secret or other confidential research, development, or
`
`commercial information” under Fed. R. Civ. P. 26(c)(1)(G) and 37 C.F.R. §
`
`42.54(a) and should be subject to the protection of the Board’s Default
`
`Protective Order. Patent Owner and Petitioner previously moved to seal,
`- 6 -
`
`
`
`
`
`among other exhibits, Exhibits 1063, 2049, and 2050. Papers 19, 42.
`
`IPR2023-00481
`Motion to Seal
`
`
`b. Public Disclosure of Patent Owner’s Demonstrative Exhibits
`Would Result In Concrete Harm to Patent Owner and Non-
`Parties
`Patent Owner would suffer several concrete harms from the public
`
`disclosure of Patent Owner’s Demonstrative Exhibits. Patent Owner’s
`
`Demonstrative Exhibits include excerpts that detail Patent Owner’s
`
`confidential drug development activities. Accordingly, public access to this
`
`information risks unfair competitive disadvantage to Patent Owner and non-
`
`parties Ares Trading S.A. and IVAX. Moreover, Patent Owner is subject to
`
`contractual obligations of confidentiality concerning Exhibits 2048, 2049,
`
`and 2050 and the exhibits and papers quoting or excerpting them, including
`
`Patent Owner’s Demonstrative Exhibits. Public disclosure of the contents of
`
`Patent Owner’s Demonstrative Exhibits would conflict with Patent Owner’s
`
`obligations.
`
`c. There is a Genuine Need for Exhibits 1063, 2049, and 2050 in
`This Proceeding
`There exists a genuine need to rely on Exhibits 1063, 2049, and 2050
`
`in the trial. Confidential information in Exhibits 1063, 2049, and 2050 are
`
`pertinent to the disputed issue of whether the asserted invalidating art is prior
`
`art under Pre-AIA 35 U.S.C. §102. This confidential information is not
`
`available from any non-confidential sources and supports Patent Owner’s
`- 7 -
`
`
`
`
`
`argument that disclosures of a dosing regimen in the asserted Bodor reference
`
`IPR2023-00481
`Motion to Seal
`
`
`is not “by another” as required by § 102(a) and (e). Patent Owner Owner’s
`
`Demonstratives include confidential excerpts of 1063, 2049, and 2050 to
`
`illustrate for the Board some of the portions of Exhibits 1063, 2049, and 2050
`
`that are genuinely needed in the trial.
`
`d. Maintaining Confidentiality of Patent Owner’s
`Demonstrative Exhibits Outweighs the Public Interest in an
`Open Record
`Although the public has an interest in the Patent Office maintaining a
`
`complete and comprehensive file history, the public interest would not be
`
`harmed by sealing Patent Owner’s Demonstrative Exhibits and the need for
`
`confidentiality outweighs any risk of such harm. The excerpts of Exhibits
`
`1063, 2049, and 2050 included in Patent Owner’s Demonstrative Exhibits
`
`concern the details of IVAX and Serono’s joint development and research
`
`efforts, and if publicly disclosed, risk competitive harm to Patent Owner and
`
`non-parties Ares Trading S.A. and IVAX (now Teva). In contrast, sealing
`
`Patent Owner’s Demonstrative Exhibits deprives the public of only
`
`confidential details of Patent Owner and non-parties that are routinely
`
`maintained confidential in inter partes review proceedings and district court
`
`litigation. For example, the Board has previously held that confidential
`
`information in a license and collaboration agreement, like the one referenced
`
`
`
`- 8 -
`
`
`
`here, should remain under seal. See, e.g., Westinghouse Air Brake
`
`IPR2023-00481
`Motion to Seal
`
`
`Technologies Corporation v. Siemens Mobility, Inc., IPR2017-01669, Paper
`
`60 (P.T.A.B. January 8, 2019). On balance, the preceding factors weigh in
`
`favor of sealing Patent Owner’s Demonstrative Exhibits.
`
`For the foregoing reasons, Patent Owner respectfully requests the
`
`Board seal Patent Owner’s Demonstrative Exhibits. The parties are awaiting
`
`the Board’s guidance regarding treatment of confidential information at the
`
`oral hearing. See Paper 50, 3-4. Patent Owner will, at the Board’s request,
`
`submit a redacted version of Patent Owner’s Demonstrative Exhibits.
`
`V. PROTECTIVE ORDER
`
`Patent Owner filed an Unopposed Motion for Entry of Default
`
`Protective Order on December 21, 2023. Paper 19.
`
`VI. CONCLUSION
`
`For the foregoing reasons, Patent Owner respectfully requests that the
`
`Board grant this Motion to Seal Patent Owner’s Demonstrative Exhibits.
`
`
`
`
`
`
`
`Dated: June 20, 2024
`
`
`Respectfully Submitted,
`
`/Emily R. Whelan/
`Emily R. Whelan (Reg. No. 50,391)
`- 9 -
`
`
`
`IPR2023-00481
`Motion to Seal
`
`
`Counsel for Patent Owner
`Wilmer Cutler Pickering Hale and Dorr
`LLP
`60 State Street
`Boston, MA 02109
`Tel. (617) 526-6567
`E-mail: emily.whelan@wilmerhale.com
`
`
`
`
`
`
`
`
`- 10 -
`
`
`
`CERTIFICATE OF SERVICE
`
`IPR2023-00481
`Motion to Seal
`
`
` hereby certify that on June 20, 2024, I caused a true and correct copy of the
`
` I
`
`below documents:
`
` Patent Owner’s Unopposed Motion to Seal Patent Owner’s
`
`Demonstrative Exhibits and
`
` Patent Owner’s Demonstrative Exhibits
`
`to be served via e-mail, as consented to by Petitioner, to:
`
`eellison-PTAB@sternekessler.com
`opartington-PTAB@sternekessler.com
`cvira-PTAB@sternekessler.com
`jcrozendaal-PTAB@sternekessler.com
`cdashe-PTAB@sternekessler.com
`pkhanduri-PTAB@sternekessler.com
`tliu-PTAB@sternekessler.com
`mbond-PTAB@sternekessler.com
`PTAB@sternekessler.com
`
`
`
`By: /Cindy Kan/
`Cindy Kan (Reg. No. 76,385)
`Wilmer Cutler Pickering Hale and Dorr LLP
`7 World Trade Center
`250 Greenwich Street
`New York, NY 10007
`Tel: (212) 295-6470
`E-mail: cindy.kan@wilmerhale.com
`
`
`
`- 11 -
`
`
`
`
`
`